Yüklüyor......
Both cladribine and alemtuzumab may effect MS via B-cell depletion
OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...
Kaydedildi:
| Yayımlandı: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Lippincott Williams & Wilkins
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5459792/ https://ncbi.nlm.nih.gov/pubmed/28626781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000360 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|